Reagents and instruments for immunology, cell biology and molecular biology.
 
> S7 TFA

S7 TFA

Print Print
Please log in

Cat# NB-64-44271-25mg

Size : 25mg

Brand : Neo Biotech

Contact local distributor :


Phone : +1 850 650 7790

S7 TFA (Synonyms: Leu-Ser-Leu-Iso-Thr-Arg-Leu-OH)

Catalog No. T83741 Copy Product Info
S7, a peptide antagonist of the IL-6 receptor, concentration-dependently inhibits IL-6 binding to its receptor. At 50 µM, S7 suppresses IL-6-triggered elevations in VEGF levels within C-33 A cervical cancer cells and RPMI-8226 B cell lymphocytes. It significantly reduces tumor volume in a C-33 A cervical cancer mouse xenograft model with IL-6 overexpression, following a dosage regimen of 50 mg/kg bi-daily. Moreover, when linked to cysteine on lipid nanoparticles (LNPs) encapsulating doxorubicin, S7 enhances glioma targeting and improves survival rates in a U251 glioblastoma mouse xenograft model.

S7 TFA

Copy Product Info
Synonyms Leu-Ser-Leu-Iso-Thr-Arg-Leu-OH

S7, a peptide antagonist of the IL-6 receptor, concentration-dependently inhibits IL-6 binding to its receptor. At 50 µM, S7 suppresses IL-6-triggered elevations in VEGF levels within C-33 A cervical cancer cells and RPMI-8226 B cell lymphocytes. It significantly reduces tumor volume in a C-33 A cervical cancer mouse xenograft model with IL-6 overexpression, following a dosage regimen of 50 mg/kg bi-daily. Moreover, when linked to cysteine on lipid nanoparticles (LNPs) encapsulating doxorubicin, S7 enhances glioma targeting and improves survival rates in a U251 glioblastoma mouse xenograft model.

S7 TFA
Other Forms of S7 TFA:

Resource Download

Product Introduction
Bioactivity
Description
S7, a peptide antagonist of the IL-6 receptor, concentration-dependently inhibits IL-6 binding to its receptor. At 50 µM, S7 suppresses IL-6-triggered elevations in VEGF levels within C-33 A cervical cancer cells and RPMI-8226 B cell lymphocytes. It significantly reduces tumor volume in a C-33 A cervical cancer mouse xenograft model with IL-6 overexpression, following a dosage regimen of 50 mg/kg bi-daily. Moreover, when linked to cysteine on lipid nanoparticles (LNPs) encapsulating doxorubicin, S7 enhances glioma targeting and improves survival rates in a U251 glioblastoma mouse xenograft model.
SynonymsLeu-Ser-Leu-Iso-Thr-Arg-Leu-OH
Chemical Properties
Molecular Weight815.01
FormulaC37H70N10O10.XCF3COOH
SmilesOC(C(F)(F)F)=O.CC(C)C[C@H](N)C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(O)=O)CC(C)C)=O)=O)=O)=O)=O)=O
SequenceLeu-Ser-Leu-Ile-Thr-Arg-Leu
Sequence ShortLSLITRL
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
1% HCOOH/H2O: Soluble